Oric Pharmaceuticals, INC 10-Q quarterly reports

Oric Pharmaceuticals disclosed its second-quarter 2026 financial results, highlighting progress in its rinzimetostat and enozertinib clinical programs while reporting a net loss of $41.5 million.

Oric Pharmaceuticals reported increased R&D expenses and a net loss for Q1 2026, while advancing its rinzimetostat and enozertinib clinical programs and raising capital through ATM offerings.

ORIC Pharmaceuticals maintains a robust financial position into H2 2028, driven by recent capital raises and reports promising Phase 1b data for ORIC-944 in mCRPC.

ORIC Pharmaceuticals reports increased cash reserves and a strategic pipeline prioritization to advance its lead cancer drug candidates, ORIC-944 and ORIC-114, despite growing net losses.

ORIC Pharmaceuticals reports a net loss of $30.0 million for Q1 2025 and provides updates on its clinical programs, including ORIC-944 and ORIC-114.

ORIC Pharmaceuticals' third quarter 2024 report highlights increased R&D spending, a net loss, and sufficient cash to fund operations into late 2026.

ORIC Pharmaceuticals reported a net loss of $57.0 million for the first six months of 2024, while highlighting progress in clinical trials and collaborations.

ORIC Pharmaceuticals reported a net loss of $25.0 million for the first quarter of 2024, while highlighting progress in its clinical programs and a recent $125 million private placement.